2026-01-18 - Analysis Report
**Company Overview**
Novo Nordisk A/S ADR is a multinational pharmaceutical company that delivers innovative solutions for people with diabetes, hemophilia, growth hormone disorders, and beyond.

**Return Rate Comparison**
| Period | NVO Rate | VOO Rate | Divergence | Relative Divergence |
| --- | --- | --- | --- | --- |
| 2022-2024 | 18.0% | 93.36% | -75.36% | 19.30% |
| 2023-2025 | -52.0% | N/A | N/A | N/A |

**Stock Price Fluctuations (SMA)**
* Close: $62.33
* Last-market: +$9.12
* 5-day SMA: $59.57
* 20-day SMA: $54.41
* 60-day SMA: $50.73

**Technical Analysis Indicators**
* Market Risk Indicator (MRI): 0.80
* RSI: 76.91
* PPO: 1.05
* Expected Return: 216.00%
* Recent (20 days) relative divergence change: +4.60 ( improving)

**Recent News & Significant Events**
* [2026-01-16] Stocks making the biggest moves midday: Novo Nordisk, Vistra, GE Vernova, Regions Financial and more - CNBC
* [2026-01-16] Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch - CNBC
* [2026-01-16] Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? - The Motley Fool
* [2026-01-16] Novo's Wegovy Pill Looks A Lot Like Zepbound — In One Week - Investor's Business Daily
* [2026-01-16] LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling - Yahoo Finance
* [2026-01-16] NVO Stock Is Rising Pre-Market – What Is The Wegovy News Driving Novo Nordisk Shares? - Stocktwits

**Analyst Opinions**
* Analyst Consensus:
  * Key: Buy
  * Mean (1=StrongBuy~5=Sell): 2.38 (~Buy)
  * Opinions: 11
  * Target Price (avg/high/low): 55.78 / 73.15 / 41.48

**Comprehensive Analysis (Summary)**
Novo Nordisk A/S ADR has a relatively low cumulative return compared to the S&P 500. The company's return has been steadily increasing, with a recent relative divergence change of +4.60 (improving). Recent market fluctuations are reflected in the stock price, with a 5-day SMA of $59.57. The Market Risk Indicator is 0.80, indicating a medium-risk investment at this time. Expected Return is 216.00%. Recent news indicates that Novo Nordisk's shares have risen 8% after the obesity pill Wegovy had a 'solid' launch. Analyst opinions are generally positive, with a mean rating of 2.38 (~Buy) and a target price of $55.78.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.